296 related articles for article (PubMed ID: 19363281)
21. Plasma and peritoneal endothelin levels and blood pressure in CAPD patients with or without erythropoietin replacement therapy.
Lebel M; Moreau V; Grose JH; Kingma I; Langlois S
Clin Nephrol; 1998 May; 49(5):313-8. PubMed ID: 9617496
[TBL] [Abstract][Full Text] [Related]
22. Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: their relationship with transport parameters.
Lai KN; Lai KB; Szeto CC; Ho KK; Poon P; Lam CW; Leung JC
Am J Kidney Dis; 1997 May; 29(5):699-705. PubMed ID: 9159303
[TBL] [Abstract][Full Text] [Related]
23. Systemic and intraperitoneal proinflammatory cytokine profiles in patients on continuous ambulatory peritoneal dialysis.
Maksic D; Vasilijic S; Colic M; Stankovic-Popovic V; Bokonjic D
Adv Perit Dial; 2009; 25():50-5. PubMed ID: 19886317
[TBL] [Abstract][Full Text] [Related]
24. Systemic and intraperitoneal proinflammatory cytokines profiles in patients on chronic peritoneal dialysis.
Maksić D; Colić M; Stanković-Popović V; Radojević M; Bokonjić D
Med Pregl; 2007; 60 Suppl 2():53-7. PubMed ID: 18928158
[TBL] [Abstract][Full Text] [Related]
25. Necessity of correcting cancer antigen 125 appearance rates by body surface area.
Kawanishi H; Moriishi M; Harada Y; Sakikubo E; Nagai T; Tsuchiya S
Adv Perit Dial; 2000; 16():22-5. PubMed ID: 11045255
[TBL] [Abstract][Full Text] [Related]
26. Cell-free DNA in the peritoneal effluent of peritoneal dialysis solutions.
Pajek J; Kveder R; Gucek A; Skoberne A; Bren A; Bucar M; Cerne D; Lukac-Bajalo J
Ther Apher Dial; 2010 Feb; 14(1):20-6. PubMed ID: 20438516
[TBL] [Abstract][Full Text] [Related]
27. Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients.
Lopes Barreto D; Coester AM; Noordzij M; Smit W; Struijk DG; Rogers S; de Waart DR; Krediet RT
Nephrol Dial Transplant; 2011 Nov; 26(11):3739-44. PubMed ID: 21498425
[TBL] [Abstract][Full Text] [Related]
28. Serum concentrations and peritoneal loss of growth hormone and growth-hormone-binding protein activity in older adults undergoing continuous ambulatory peritoneal dialysis: comparison with haemodialysis patients and normal subjects.
Kagan A; Zadik Z; Gertler A; Ulman M; Bar-Khayim Y
Nephrol Dial Transplant; 1993; 8(4):352-6. PubMed ID: 8390011
[TBL] [Abstract][Full Text] [Related]
29. Transport of peritoneal membrane assessed before and after the start of peritoneal dialysis.
La Milia V; Limardo M; Cavalli A; Crepaldi M; Locatelli F
Nephrol Dial Transplant; 2009 Sep; 24(9):2894-8. PubMed ID: 19349295
[TBL] [Abstract][Full Text] [Related]
30. Influence of pH-neutral peritoneal dialysis solution.
Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
Adv Perit Dial; 2002; 18():68-71. PubMed ID: 12402590
[TBL] [Abstract][Full Text] [Related]
31. Relationship of IgG, C3 and transferrin with opsonising and bacteriostatic activity of peritoneal fluid from CAPD patients and the incidence of peritonitis.
McGregor SJ; Brock JH; Briggs JD; Junor BJ
Nephrol Dial Transplant; 1987; 2(6):551-6. PubMed ID: 3126457
[TBL] [Abstract][Full Text] [Related]
32. Effects of glucose-free dialysis solutions on human peritoneal mesothelial cells.
Chang JM; Lin SP; Lai YH; Chen HC
Am J Nephrol; 2007; 27(2):206-11. PubMed ID: 17377374
[TBL] [Abstract][Full Text] [Related]
33. Expression of cancer antigen 125 by peritoneal mesothelial cells is not influenced by duration of peritoneal dialysis.
Sanusi AA; Zweers MM; Weening JJ; de Waart DR; Struijk DG; Krediet RT
Perit Dial Int; 2001; 21(5):495-500. PubMed ID: 11757834
[TBL] [Abstract][Full Text] [Related]
34. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.
Do JY; Kim YL; Park JW; Chang KA; Lee SH; Ryu DH; Kim CD; Park SH; Yoon KW
Perit Dial Int; 2008 Jun; 28 Suppl 3():S101-6. PubMed ID: 18552237
[TBL] [Abstract][Full Text] [Related]
35. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
36. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis.
Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
Adv Perit Dial; 2002; 18():149-53. PubMed ID: 12402608
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of body size indices, residual renal function, and peritoneal transport characteristics in continuous ambulatory peritoneal dialysis.
Twardowski ZJ; Moore HL; Prowant BF; Satalowich R
Adv Perit Dial; 2009; 25():155-64. PubMed ID: 19886338
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of the dialysis adequacy and transport test in peritoneal dialysis.
Seo JJ; Kim YL; Park SH; Kim CD; Kim JC; Jang MH; Choi HJ
Adv Perit Dial; 2005; 21():25-30. PubMed ID: 16686280
[TBL] [Abstract][Full Text] [Related]
39. The relationship between peritoneal transport characteristics and messenger RNA expression of aquaporin in the peritoneal dialysis effluent of CAPD patients.
Szeto CC; Lai KB; Chow KM; Szeto CY; Li PK
J Nephrol; 2005; 18(2):197-203. PubMed ID: 15931648
[TBL] [Abstract][Full Text] [Related]
40. Is interleukin-6 concentration in the dialysate of continuous ambulatory peritoneal dialysis patients a prognostic parameter in peritonitis?
Fiedler R; Schneider I; Fischer K; Deuber HJ; Osten B
Adv Perit Dial; 2001; 17():159-62. PubMed ID: 11510267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
